Skip to main content
. 2021 Apr 30;16(4):e0250228. doi: 10.1371/journal.pone.0250228

Fig 3. During the latter treatment phases, intravenous folinic acid administration reduced the highly elevated CSF levels of Tau (but not pTau) in methylenetetrahydrofolate reductase (MTHFR) MTHFR1298CC individuals.

Fig 3

Methotrexate (MTX) treatment was continued (black vertical arrows at the top of each figure). Panels A-B depict CSF Tau (A) and pTau (B) levels during the interval and reinduction phases (lumbar puncture, LP6-10). Initially elevated CSF Tau (but not pTau) levels (LP6), equalized after intravenous folinic acid administration (LP7-10, green vertical arrows). Panels C-D depict CSF biomarker levels during the maintenance phase. CSF pTau differed significantly between genotypes (D), whereas Tau did not (C). MTHFR genotype is indicated with color in all panels (red: MTHFR1298CC, blue: MTHFR1298AC, black: MTHFR1298AA). Appropriate ANOVA was followed by post-hoc LSD with * p < 0.05; ** p < 0.010; *** p< <0.001.